Approved for use through 07/31/2005 OMB 0651-2031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE o a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		
Filing Date		
First Named Inventor	Gilles	Darras
Art Unit		
Examiner Name		
Attornov Docket Numb	or.	AD002 06

				U.S.	PATENTS		Remove
Examiner Initial*			Releva	Columns,Lines where nt Passages or Relevant s Appear			
	1	5945787	A	1999-08-31 Gcrille et al.			
	2	4358716	A	1982-11-09	32-11-09 Cordes et al.		
	3	6453217	B1	2002-09-17	Takita Hiroki		
	4	4388563	A	1983-06-14	Hyttin et al.		
	5	5962989	A	1999-10-05	Baker et al.		
	6	4488088	A	1984-12-11	Paget et al.		
If you wish	to ac	dd additional U.S. Pater	t citatio	n information pl	lease click the Add button.		Add
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Releva	Columns,Lines where nt Passages or Relevant Appear

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		
Filing Date		
First Named Inventor	Gilles	Darras
Art Unit		
Examiner Name		
Attorney Docket Number		AP093-06

	1	2002	0153852	A1	2002-1	0-24	Liao Yu-Shih et al.						
If you wish to add additional U.S. Published Application citation information please click the Add button. Add													
					FOREIG	SN PAT	TENT DOCUM	ENT	s		Remove		
Examiner Initial*	Cite No				Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document		or	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear		TS	
	1												
If you wish to add additional Foreign Patent Document citation information please click the Add button Add													
NON-PATENT LITERATURE DOCUMENTS Remove													
Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item Initials* No (book, magazine, journal, serial, symposium, catalog, etc), data, pages(s), volume-issue number(s), publisher, city andor country when published.							T5						
	1												
If you wish to add additional non-patent literature document citation information please click the Add button Add													
					EX	AMINE	R SIGNATUR	E					
Examiner	Signa	ture						$\neg \neg$	Date Conside	red			

1 Sex Knc Codes of USPTO Potent Documents at sweep USPTO_CODY or MEPS 901.6. I Enter office that assed the document, by the televister code (MPDO Standard 57.3.) "For Superinse patient coursets, the reduced on the year of the register completes the sextle attack of the Properties and procedule is well as the Companies of the Properties and procedule is and an extra first and the document by the appropriate symbols as indicated on the document under WIPO Standard 57.16 if possible. If Applicant is to place a choick mark here if

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Application Number Filing Date STATEMENT BY APPLICANT (Not for submission under 37 CFR 199) Application Number Gilles Darras Art Unit Examiner Name Attorney Docket Number AP090-06

CERTIFICATION STATEMENT

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eVI).

ΩR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of information contained in the information disclosure statement was known to any individual designated in 37 CFR 15(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement. See 37 CFR 157(c) for the filing of the information disclosure statement.

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

7 None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/David A. Guerra	Date (YYYY-MM-DD)	2006-04-21
Name/Print	David A. Guerra	Registration Number	46443

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentially is governed by \$5 U.S. C.12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patient and Tradenant's Office, U.S. operationed for Commence, P. 0. Bot 1450, Alexandria, V.S. 2213.1-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.2.2313.1-1450.

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant for the control of t
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.